IRIS
CEA, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 9.871
Totale 9.871
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 9.871
Totale 9.871
Salva come PNG Salva come JPEG
Città #
Genova 6.930
Genoa 1.392
Rapallo 1.149
Vado Ligure 379
Bordighera 21
Totale 9.871
Salva come PNG Salva come JPEG
Nome #
Regulation and Function of Extracellular Nicotinamide Phosphoribosyltransferase/Visfatin. 179
Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of AKT-mediated gene repression 176
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 171
Autophagy in blood cancers: biological role and therapeutic implications. 168
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 168
APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment 163
Nicotinic acid phosphoribosyltransferase regulates cancer cell metabolism, susceptibility to NAMPT inhibitors and DNA repair. 163
SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells 156
APO866 activity in hematologic malignancies: a preclinical in vitro study. 152
Ras-induced resistance to lapatinib is overcome by MEK inhibition 147
Monoclonal antibodies for non-Hodgkin's lymphoma: state of the art and perspectives. 145
The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival 142
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 140
Nicotinamide Phosphoribosyltransferase (Nampt) Inhibitors As Therapeutics: Rationales, Controversies, Clinical Experience. 139
Catastrophic NAD(+) Depletion in Activated T Lymphocytes through Nampt Inhibition Reduces Demyelination and Disability in EAE 139
SIRT6 inhibitors with salicylate-like structure show immunosuppressive and chemosensitizing effects 137
Sirt6 regulates dendritic cell differentiation, maturation, and function 136
Peripheral blood vs. bone marrow for molecular monitoring of BCR-ABL1 levels in chronic myelogenous leukemia, a retrospective analysis in allogeneic bone marrow recipients. 136
Treatment with KLEPTOSE® CRYSMEB reduces mouse atherogenesis by impacting on lipid profile and Th1 lymphocyte response 133
Intraplaque Expression of C-Reactive Protein Predicts Cardiovascular Events in Patients with Severe Atherosclerotic Carotid Artery Stenosis 132
Nicotinamide phosphoribosyltransferase promotes epithelial-to-mesenchymal transition as a soluble factor independent of its enzymatic activity. 130
Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more. 130
EIF2A-dependent translational arrest protects leukemia cells from the energetic stress induced by NAMPT inhibition 129
CXCR4 regulates extra-medullary myeloma through epithelial-mesenchymal-transition-like transcriptional activation 127
Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma 127
Induction of cell killing and autophagy by amphiphilic pyrrolidine derivatives on human pancreatic cancer cells 127
Synthesis of Pyrrolidine 3,4-Diol Derivatives with Anticancer Activity on Pancreatic Tumor Cells 123
New insights into biology of chronic myeloid leukemia: implications in therapy. 122
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 121
Evaluation of prognostic indices in elderly hospitalized patients 121
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 120
Fasting potentiates the anticancer activity of tyrosin kinase inhibitors by strenghtening MAPK signalling inhibition. 120
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 118
Nicotinamide Phosphoribosyltransferase As A Target In Inflammation-Related Disorders. 117
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 114
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 113
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 113
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 111
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 111
Longitudinal minimal residual disease (MRD) evaluation in acute myeloid leukaemia with NPM1 mutation: from definition of molecular relapse to MRD-driven salvage approach 108
Synthesis and cancer growth inhibitory activities of 2-fatty-alkylated pyrrolidine-3,4-diol derivatives 107
Potent synergistic interaction between the Nampt inhibitor APO866 and the apoptosis activator TRAIL in human leukemia cells. 106
Anti-cancer activity of 5-O-alkyl 1,4-imino-1,4-dideoxyribitols. 105
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 105
CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: Molecular mechanisms and therapeutic implications 104
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 103
Biological Insights into Myeloma and Other B Cell Malignancies 103
Intracellular NAD+ depletion induces autophagic-death in Multiple Myeloma cells 103
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 103
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 103
Synthesis of new oxathiazinane dioxides and their in vitro cancer cell growth inhibitory activity. 99
Predictive values of two frailty screening tools in older patients with solid cancer: a comparison of SAOP2 and G8 99
Novel 2-[(benzylamino)methyl]pyrrolidine-3,4-diol derivatives as alpha-mannosidase inhibitors and with antitumor activities against hematological and solid malignancies. 96
Catastrophic NAD+ Depletion through Nampt Inhibition in Activated T Lymphocytes Reduces Demyelination and Disability in EAE. 95
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 93
Differentiating diffuse from focal pattern on Computed Tomography in multiple myeloma: Added value of a Radiomics approach 93
Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma 92
null 91
Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma 90
Targeting Inflammation in Primary Cardiovascular Prevention 90
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 89
The NAD+-dependent histone deacetylase SIRT6 promotes cytokine production and migration in pancreatic cancer cells by regulating Ca2+ responses. 88
Long non-coding RNA NEAT1 targeting impairs the DNA repair machinery and triggers anti-tumor activity in multiple myeloma 88
Nutrients in the Prevention of Alzheimer's Disease 85
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 84
SIRT6 inhibition as a novel approach for treating Acute Myeloid Leukemia 84
Abstract CT075: Fasting-mimicking diet and hormone therapy modulates metabolic factors to promote breast cancer regression and reduce side effects 84
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 82
Radiomics and artificial intelligence analysis of CT data for the identification of prognostic features in multiple myeloma 78
Current standards and future strategies in immunochemotherapy of non-Hodgkin's lymphoma. 75
Synergistic Interaction Between P-glycoprotein Inhibitors and APO866 in Primary Leukemic Cells 74
Fasting-mimicking diet and hormone therapy induce breast cancer regression 72
Safety and feasibility of fasting‐mimicking diet and effects on nutritional status and circulating metabolic and inflammatory factors in cancer patients undergoing active treatment 72
The Novel Phosphatidylinositol-3-Kinase (PI3K) Inhibitor Alpelisib Effectively Inhibits Growth of PTEN-Haploinsufficient Lipoma Cells 68
Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells 68
Pharmacological Sirt6 inhibition improves glucose tolerance in a type 2 diabetes mouse model 67
Radiomics and artificial intelligence for outcome prediction in multiple myeloma patients undergoing autologous transplantation: A feasibility study with ct data 65
SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice 64
Amino acid depletion triggered by L-asparaginase sensitizes MM cells to carfilzomib by inducing mitochondria ROS-mediated cell death 63
null 61
Depletion of the intracellular coenzyme NAD plus in activated T-cells ameliorates experimental autoimmune encephalomyelitis 61
Potent Synergistic Activity of the NAD plus Synthesis Inhibitor APO866 and of the Apoptosis Inducer TRAIL in in Vitro and Ex Vivo Cellular Models of Non Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia. 60
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of flt3-itd in npm1 mutated aml, irrespectively of flt3-itd allelic Burden 60
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 58
CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD+-Lowering Agents 53
Harnessing Immune Response in Acute Myeloid Leukemia 52
Post-Transplant Nivolumab Plus Unselected Autologous Lymphocytes in Refractory Hodgkin Lymphoma: A Feasible and Promising Salvage Therapy Associated With Expansion and Maturation of NK Cells 50
Chronic myeloid leukemia: Reaching for the cure 50
Apoptosis reprogramming triggered by splicing inhibitors sensitizes multiple myeloma cells to Venetoclax treatment 49
Dual NAMPT and BTK targeting leads to synergistic killing of Waldenström macroglobulinemia cells regardless of MYD88 and CXCR4 somatic mutation status 49
Fasting-mimicking diet and hormone therapy induce breast cancer regression 49
Nicotinic acid phosphoribosyltransferase is overexpressed in solid tumors and regulates cancer cell metabolism and susceptibility to FK866 43
Resistin, oxidative stress and amyloid beta: a possible link in Alzheimer' disease 40
The non-coding RNA landscape of plasma cell dyscrasias 40
Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial 38
A real-world efficacy and safety analysis of combined carfilzomib, lenalidomide, and dexamethasone (KRd) in relapsed/refractory multiple myeloma 37
Reactive oxygen/nitrogen species contribute substantially to the antileukemia effect of APO866, a NAD lowering agent 36
Cyclic fasting bolsters cholesterol biosynthesis inhibitors' anticancer activity 34
Effect of Geriatric Comanagement in Older Patients Undergoing Surgery for Gastrointestinal Cancer: A Retrospective, Before-and-After Study 33
A Blastic Plasmacytoid Dendritic Cell Neoplasm-like Phenotype Identifies a Subgroup of NPM1-Mutated AML Patients with Worse Prognosis While Has Not Predictive Value in NPM1-Wt AML 29
Totale 9.836
Salva come PNG Salva come JPEG
Categoria #
all - tutte 34.879
article - articoli 34.241
book - libri 0
conference - conferenze 638
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 69.758
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20202.437 0 0 0 288 277 333 379 204 260 353 260 83
2020/20211.050 57 88 112 79 108 68 71 93 88 118 98 70
2021/20221.276 44 65 100 158 64 104 71 254 74 114 64 164
2022/20231.450 148 161 18 148 235 184 10 95 207 32 186 26
2023/20241.060 46 97 35 152 98 191 80 103 33 22 74 129
2024/2025479 133 198 64 84 0 0 0 0 0 0 0 0
Totale 10.187